Today The SunTrust Banks, Inc. Reaffirms “Buy” Rating for Jazz Pharmaceuticals PLC (JAZZ)

Today The SunTrust Banks, Inc. Reaffirms “Buy” Rating for Jazz Pharmaceuticals PLC (JAZZ)

SunTrust Banks, Inc. reiterated their buy rating on shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in a report issued on Thursday. SunTrust Banks, Inc. currently has a $210.00 price target on the specialty pharmaceutical company’s stock.

Other analysts have also recently issued reports about the stock. BMO Capital Markets reissued an outperform rating and set a $192.00 price objective on shares of Jazz Pharmaceuticals PLC in a research note on Thursday, January 12th. Goldman Sachs Group, Inc. (The) reissued a buy rating and set a $170.00 price objective on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, January 18th. Mizuho lowered their price objective on shares of Jazz Pharmaceuticals PLC from $185.00 to $127.00 and set a buy rating for the company in a research note on Wednesday, November 9th. Barclays PLC reissued an overweight rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, January 18th. Finally, Deutsche Bank AG reissued a buy rating and set a $148.00 price objective on shares of Jazz Pharmaceuticals PLC in a research note on Thursday, January 19th. Four investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Jazz Pharmaceuticals PLC currently has an average rating of Buy and a consensus price target of $178.25.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded up 1.0553% during mid-day trading on Thursday, reaching $121.4584. The company’s stock had a trading volume of 69,741 shares. The stock has a market capitalization of $7.27 billion, a P/E ratio of 21.2414 and a beta of 1.30. The stock’s 50 day moving average price is $111.52 and its 200 day moving average price is $122.05. Jazz Pharmaceuticals PLC has a 1-year low of $95.80 and a 1-year high of $160.00.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $2.57 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.61 by $0.04. The business earned $374 million during the quarter, compared to analyst estimates of $389.34 million. Jazz Pharmaceuticals PLC had a net margin of 24.81% and a return on equity of 30.50%. The company’s revenue was up 9.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.52 earnings per share. Analysts expect that Jazz Pharmaceuticals PLC will post $9.96 EPS for the current fiscal year.

In other Jazz Pharmaceuticals PLC news, Director Kenneth W. O’keefe acquired 2,000 shares of the company’s stock in a transaction that occurred on Monday, November 14th. The shares were purchased at an average price of $113.84 per share, for a total transaction of $227,680.00. Following the completion of the purchase, the director now directly owns 12,107 shares in the company, valued at $1,378,260.88. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Russell J. Cox sold 4,000 shares of the stock in a transaction dated Wednesday, January 18th. The stock was sold at an average price of $128.75, for a total transaction of $515,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 5,277 shares of company stock worth $650,161. Company insiders own 3.90% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. Bank of Montreal Can acquired a new stake in Jazz Pharmaceuticals PLC during the second quarter valued at $6,606,000. Strs Ohio raised its stake in Jazz Pharmaceuticals PLC by 9.9% in the second quarter. Strs Ohio now owns 177,768 shares of the specialty pharmaceutical company’s stock valued at $25,120,000 after buying an additional 16,078 shares during the period. Boston Advisors LLC raised its stake in Jazz Pharmaceuticals PLC by 470.4% in the second quarter. Boston Advisors LLC now owns 161,318 shares of the specialty pharmaceutical company’s stock valued at $22,796,000 after buying an additional 133,038 shares during the period. Capital Fund Management S.A. raised its stake in Jazz Pharmaceuticals PLC by 116.5% in the second quarter. Capital Fund Management S.A. now owns 73,727 shares of the specialty pharmaceutical company’s stock valued at $10,418,000 after buying an additional 39,673 shares during the period. Finally, CG Asset Management LLC raised its stake in Jazz Pharmaceuticals PLC by 24.8% in the second quarter. CG Asset Management LLC now owns 34,460 shares of the specialty pharmaceutical company’s stock valued at $4,870,000 after buying an additional 6,840 shares during the period. Hedge funds and other institutional investors own 89.20% of the company’s stock.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Related posts

Leave a Comment